Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, according to research ...
ORLANDO – Maintenance doses of the biologic agent infliximab (Remicade) can be safely administered at a patient's home with a very low rate of adverse events (AEs) and serious AEs, a researcher ...
Please provide your email address to receive an email when new articles are posted on . In a prospective, observational cohort study, researchers evaluated 186 patients with IBD previously dosed with ...
Infliximab (Remicade, Schering-Plough Ltd) is a tumour necrosis factor alpha (TNF-α) inhibitor and has a UK marketing authorisation for the treatment of moderately to severely active ulcerative ...
Findings from the extended LIBERTY studies and associated post-hoc analysis support the long-term efficacy and safety of ZYMFENTRA™, the first and only FDA-approved subcutaneous infliximab [1],[2] ...
Napp Pharmaceuticals has bagged exclusive rights to distribute Celltrion’s biosimilar of Johnson & Johnson and Merck & Co's anti-inflammatory blockbuster Remicade in the UK. Napp Pharmaceuticals has ...
The UK's National Health Service may have reaped the cost-saving benefits of Celltrion's biosimilar of the inflammatory diseases drug Remicade (infliximab) had it planned a pricing and reimbursement ...
INCHEON, Korea, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. today announced results from two real-world studies of RENFLEXIS ® (infliximab-abda) in patients with Inflammatory Bowel ...
In a double-blind multicenter study by Targan et al., [50] 108 patients with active, refractory, moderate to severe CD (a mean CDAI score at baseline of approximately 300 despite treatment with ...
The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by ...
Infliximab is an efficacious treatment for rheumatoid arthritis (RA). The recommended treatment schedule, however, is unsatisfactory in a substantial subset of patients. This study was an open-label ...
Infliximab (Remicade, Schering-Plough) is indicated for the treatment of moderate to severe plaque psoriasis in adults whose condition has failed to respond to, or who have a contraindication to, or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback